TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Sponsor: Aulos Bioscience, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 159 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,356,200

Rescue Site Savings

+$1,570,800

Unlock Full NCT05267626 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05267626 Rescue Dossier →